Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-024 as a Single Dose in Healthy Overweight and Obese Participants and as Multiple Doses in Participants With Type 2 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A First-In-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-024 as a Single Dose in Healthy Overweight and Obese Participants and as Multiple Doses in Participants With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GFB 024 (Primary)
  • Indications Diabetic nephropathies; Focal segmental glomerulosclerosis; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Goldfinch Bio

    • Most Recent Events

    • 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
    • 31 May 2022 According to a Goldfinch Bio media release, data from this study will be presented at the Endocrine Society's Annual Meeting, ENDO 2022 and American Diabetes Association (ADA) 82nd Scientific Sessions.
    • 24 Mar 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top